Cross-sectional studies reported that hepatitis B core gene mutations are associated with active liver disease and responsiveness to interferon therapy. In view of the heterogeneity in published sequences, it is not possible to tell whether the differences in sequences observed were true mutations t
Different composition of intrahepatic lymphocytes in the immune-tolerance and immune-clearance phase of chronic hepatitis B
β Scribed by D. Sprengers; R.G. van der Molen; J.G. Kusters; B. Hansen; H.G.M. Niesters; S.W. Schalm; H.L.A. Janssen
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 158 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
β¦ Synopsis
Based on virological and biochemical parameters patients with chronic hepatitis B virus (HBV) are divided into distinct clinical phases: the immunetolerance phase, the immune-clearance phase, and the inactive carrier state. Unclear is whether these phases have characteristic intrahepatic immune responses. The composition of liverderived lymphocytes in patients with chronic HBV infection was studied. In 47 patients the composition of liver-derived lymphocytes was analyzed by flow cytometry of fine needle aspiration biopsies of the liver. The proportion natural killer (NK) cells in the liver was significantly higher in immune-tolerant than in immuneclearance patients and inactive carriers. No differences were found in proportion CD4ΓΎ T-cells and CD8ΓΎ T-cells, in these phases. However, when patients in the immune-clearance phase, with similar alanine transaminase (ALT), were grouped according to viral load, the proportion CD8ΓΎ T-cells was higher in those with high viral load. In contrast, the proportion CD4ΓΎ T-cells was increased in patients with low HBV-DNA. These differences were absent in the peripheral blood (PB). Intrahepatic HBV-specific CD8ΓΎ T-cells were mainly found in immune-clearance patients with low viral load. In conclusion, clear differences in the intrahepatic cellular infiltrate were found between the various clinical phases of chronic HBV infection. These findings are relevant to the design of new, individualized anti-viral strategies.
π SIMILAR VOLUMES
Individuals with chronic hepatitis B virus (HBV)
IFN-a and lamivudine, were treated with 16 weeks of 10 megaunits PBMC, peripheral blood mononuclear cell; SI, stimulation index; ALT, alanine transami-of recombinant IFN-a 2b (Intron-A; Schering-Plough, Welwyn Garnase. den City, England) subcutaneously three times a week and 100 mg From the Institu
Because cellular and humoral immune responses against the hepatitis B virus (HBV) surface antigen (HBs) might be crucial to overcome HBV infection, HBs-specific B-and T-cell responses of HBV patients and HBs vaccine recipients were analyzed quantitatively and functionally. In patients with acute hep